METABOLIC & WEIGHT RESEARCH / FAQ
Questions From the Research Record
Direct, citation-anchored answers to the questions readers most often bring to MOTS-c, tesamorelin, and tirzepatide.
What does the MOTS-c peptide do?
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA that, in cell and animal research, inhibits folate-cycle enzymes to activate AMPK — a cellular energy-sensing switch — and directly binds and activates casein kinase 2 (CK2) in a tissue-specific way that improves muscle glucose uptake and helps prevent muscle atrophy in mouse models [1]. It also translocates to the cell nucleus under metabolic stress to help regulate stress-response genes [5]. No completed human trial has tested what exogenous MOTS-c does in people; the strongest human data are observational associations, such as a link between circulating MOTS-c and cardiovascular risk in hemodialysis patients [2].
What are the negative side effects of MOTS-c?
Because no human clinical trial of exogenous MOTS-c has been completed, there is no established human side-effect profile in the peer-reviewed literature — a data gap, not a clean safety record. Everything published comes from cell and rodent studies, and the doses used in those studies (0.5-15 mg/kg/day) have no established human equivalent [3]. Research-chemical material sold for laboratory use is not regulated as a pharmaceutical, so its purity, identity, and sterility are not verified the way an approved drug's would be. This site does not describe or recommend a human dose for MOTS-c.
Is MOTS-c legal to buy?
MOTS-c is not approved by the FDA for any human use; it is sold only as a research chemical intended for laboratory research, not human consumption. That research-use framing is a real regulatory category — it is not the same as an approved drug being legally prescribed, nor is buying a labeled research chemical automatically illegal in most jurisdictions, but no oversight body verifies what such products actually contain. Separately, anti-doping authorities such as USADA and WADA classify MOTS-c as a prohibited substance in elite sport, so competitive athletes can face sanctions for its use regardless of how it was obtained. This is regulatory and legal information, not a recommendation to purchase or use MOTS-c.
How often do you inject MOTS-c?
There is no established human dosing schedule for MOTS-c in the peer-reviewed literature, because no completed human clinical trial has tested administering it. Published research uses daily rodent dosing regimens (0.5-15 mg/kg/day in mice and rats), which cannot be converted into a human injection frequency [3]. Chai Peptides does not provide a dosing schedule for MOTS-c or any other compound covered on this site; that is a question for a licensed clinician, and for a compound with no completed human trials, the honest answer is that the evidence needed to support any specific human schedule does not yet exist.
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analogue of human growth-hormone-releasing hormone (GHRH), chemically modified to resist rapid breakdown so it can be given once daily. It is FDA-approved for one specific use: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy [7]. It works by stimulating the pituitary gland to release the body's own growth hormone in its natural pulsatile pattern, rather than supplying growth hormone directly.
What does tesamorelin do?
In its approved population, tesamorelin reduces visceral adipose tissue — the fat stored deep around the abdominal organs — along with trunk fat and liver fat, while modestly increasing lean body mass. A 2026 meta-analysis of five randomized trials found significant reductions in all three fat measures and a significant lean-mass gain, without serious adverse events [6]. The visceral-fat effect depends on continued treatment: it re-accumulates within weeks of stopping [10].
How does tesamorelin work?
Tesamorelin binds the growth-hormone-releasing hormone receptor on pituitary cells, triggering a signaling cascade that stimulates the body's own pulsatile growth-hormone secretion. That growth hormone drives the liver to produce IGF-1, and together GH and IGF-1 promote lipolysis with a documented preference for visceral fat over other fat depots. A study in healthy men found this raised GH and IGF-1 significantly within two weeks without meaningfully affecting fasting glucose or insulin sensitivity [9].
Will tesamorelin help me lose belly fat?
In its studied population — adults with HIV-associated lipodystrophy — tesamorelin has repeatedly reduced visceral (deep abdominal) fat in randomized controlled trials, most recently confirmed by a 2026 meta-analysis of five pooled trials (mean difference -27.71 cm², P<0.001) [6]. That evidence is specific to lipodystrophy in the context of HIV and antiretroviral therapy; it is not the same as evidence for general-population weight loss or cosmetic fat reduction, and this site does not make that extrapolation. Tesamorelin is a prescription medicine used under a clinician's supervision, not a self-directed weight-loss regimen.
What is tirzepatide?
Tirzepatide is a 39-amino-acid synthetic peptide that activates two gut-hormone receptors at once — GIP and GLP-1 — making it the first approved dual incretin agonist. It is FDA-approved for type 2 diabetes mellitus, chronic weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity [12]. It is given as a once-weekly subcutaneous injection.
How does tirzepatide work?
By engaging both the GIP and GLP-1 receptors, tirzepatide enhances glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying — effects that together improve blood-sugar control and reduce appetite. In vitro work shows the engagement is imbalanced, favoring the GIP receptor, with biased GLP-1-receptor signaling proposed to enhance insulin secretion relative to a selective GLP-1 agonist [16]. In a head-to-head trial, this combination produced significantly greater weight loss than semaglutide, a selective GLP-1 agonist (-20.2% versus -13.7% over 72 weeks) [11].
What does tirzepatide do in the body?
In the pancreas, it boosts glucose-dependent insulin release and suppresses inappropriate glucagon secretion. In the gut, it slows gastric emptying, extending fullness after meals (and contributing to nausea as a side effect). In the brain, it acts on hypothalamic appetite circuits to reduce hunger and food-seeking behavior — the mechanism behind the quieter 'food noise' widely described in patient exit interviews. A SURMOUNT-1 sub-analysis found roughly three-quarters of the weight lost was fat mass, with the remainder lean mass, a pattern consistent with weight loss achieved by other means [14].
What is tirzepatide used for?
Tirzepatide's FDA-approved uses are type 2 diabetes mellitus (since May 2022), chronic weight management in adults with obesity or overweight plus a weight-related condition (since November 2023), and moderate-to-severe obstructive sleep apnea in adults with obesity [12]. In clinical research, it has also been studied directly against semaglutide, both in type 2 diabetes (SURPASS-2) [15] and in obesity (SURMOUNT-5) [11], outperforming it on weight loss in both settings.